Patents by Inventor Theodore Friedmann
Theodore Friedmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7060688Abstract: A method for gene therapy for cancers wherein chromosomal location of an inactive or defective cancer suppressing gene is established, a replacement gene which is preferably cloned is then used to replace the inactive or defective cancer suppressing gene in the chromosome. In addition to its uses in therapy, the present invention provides a means for prophylactically treating individuals having a genetic predisposition to cancer and provides an animal model for testing for carcinogenicity of environmental substances.Type: GrantFiled: December 21, 2001Date of Patent: June 13, 2006Assignee: The Regents of the University of CaliforniaInventors: Wen-Hwa Lee, Huei-Jen Sue Huang, Eva Y. H. P. Lee, Theodore Friedmann, Jiing-Kuan Yee
-
Patent number: 6451304Abstract: The invention provides a system for production of retroviruses which are replication incompetent. In the system, gag and pol retroviral structural proteins are expressed separately by different plasmids in a packaging cell line. Separate gag and pol expressing plasmids are provided, as are packaging cell lines containing such plasmids. Retrovirus products of the retroviral vector production system, including chimeric retroviruses, are also provided.Type: GrantFiled: March 9, 1999Date of Patent: September 17, 2002Assignee: The Regents of the University of CaliforniaInventors: Theodore Friedmann, Atsushi Miyanohara
-
Patent number: 6432705Abstract: The present invention features compositions and methods for the inducible expression of a polypeptide, especially a polypeptide normally cytotoxic to the eukaryotic host cell in which it is to be expressed. A nucleotide sequence encoding a polypeptide of interest is operably linked to an inducible promoter. Expression from the inducible promoter is regulated by a multi-chimeric transactivating factor, composed of a first ligand-binding domain that negatively regulates transcription, a transcriptional activation domain, and a second ligand-binding domain that positively regulates the transcriptional activation function of the transactivator. Transcription of the nucleotide sequence under control of the inducible promoter is activated by the multi-chimeric transactivator when both the ligand that binds the first ligand-binding domain is absent and the ligand that binds the second ligand-binding domain is present.Type: GrantFiled: May 8, 2000Date of Patent: August 13, 2002Assignees: The Regents of the University of California, City of HopeInventors: Jiing-Kuan Yee, Theodore Friedmann, Shin-Tai Chen
-
Patent number: 6171862Abstract: Transfection of host cells cultured in the presence of serum is increased by adding VSV-G or polybrene to a nucleic acid-lipid complex or culture medium prior to transfection.Type: GrantFiled: March 31, 1998Date of Patent: January 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Akihiro Abe, Atsushi Miyanohara, Theodore Friedmann
-
Patent number: 6133027Abstract: The present invention features compositions and methods for the inducible expression of a polypeptide, especially a polypeptide normally cytotoxic to the eukaryotic host cell in which it is to be expressed. A nucleotide sequence encoding a polypeptide of interest is operably linked to an inducible promoter (e.g, a promoter composed of a minimal promoter linked to multiple copies of tetO, the binding site for the tetracycline repressor (tetR) of the Escherichia coli tetracycline resistance operon Tn10). Expression from the inducible promoter is regulated by a multi-chimeric transactivating factor, composed of a first ligand-binding domain that negatively regulates transcription (e.g., a prokaryotic tetracycline repressor polypeptide), a transcriptional activation domain, and a second ligand-binding domain that positively regulates the transcriptional activation function of the transactivator (e.g., a ligand-binding domain of a steroid receptor, preferably an estrogen receptor (ER)).Type: GrantFiled: August 7, 1996Date of Patent: October 17, 2000Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Jiing-Kuan Yee, Theodore Friedmann, Shin-Tai Chen
-
Patent number: 5817491Abstract: An enveloped vector particle contains gag and pol proteins from a retrovirus, a nucleic acid sequence and an envelope that includes VSV G envelope glycoprotein. The vector particle can be used to introduce nucleic acids into cells.Type: GrantFiled: December 22, 1994Date of Patent: October 6, 1998Assignees: The Regents of the University of California, Chiron Viagene, Inc.Inventors: Jiing-Kuan Yee, Nobuhiko Emi, Theodore Friedmann, Douglas J. Jolly, Jack R. Barber
-
Patent number: 5762926Abstract: Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are described.Type: GrantFiled: June 5, 1995Date of Patent: June 9, 1998Assignee: The Regents of the University of CaliforniaInventors: Fred H. Gage, Malcolm Schinstine, Jasodhara Ray, Theodore Friedmann, Michael D. Kawaja, Michael B. Rosenberg, Jon A. Wolff
-
Patent number: 5739018Abstract: The present invention features packaging cell lines and recombinant retroviral particles produced thereby, particularly pseudotyped retroviral particles. Preferably, the packaging cell lines are derived from HeLa, Cf2Th, D17, MDCK, or BHK cells, most preferably from Cf2Th cells. Retroviral particles are produced by inducibly expressing an envelope protein of interest (e.g., a retroviral envelope or the envelope protein of vesicular stomatitis virus (VSV G)). Inducible expression of the envelope protein is accomplished by operably linking an envelope protein-encoding nucleotide sequence to an inducible promoter (e.g., a promoter composed of a minimal promoter linked to multiple copies of tetO, the binding site for the tetracycline repressor (tetR) of the Escherichia coli, tetracycline resistance operon Tn10).Type: GrantFiled: August 7, 1996Date of Patent: April 14, 1998Assignees: The Regents of the University of California, City of HopeInventors: Atsushi Miyanohara, Jiing-Kuan Yee, Shin-Tai Chen, Charles Edward Prussak, Theodore Friedmann
-
Patent number: 5674486Abstract: A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.Type: GrantFiled: June 6, 1995Date of Patent: October 7, 1997Assignee: San Diego Regional Cancer CenterInventors: Robert E. Sobol, Fred H. Gage, Ivor Royston, Theodore Friedmann
-
Patent number: 5670354Abstract: The present application discloses retrovirus-derived vectors in which the retroviral envelope glycoprotein has been replaced by the G glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10.sup.9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.Type: GrantFiled: June 7, 1995Date of Patent: September 23, 1997Assignee: The Regents of the University of CaliforniaInventors: Jane C. Burns, Jiing-Kuan Yee, Theodore Friedmann
-
Patent number: 5650148Abstract: Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are described.Type: GrantFiled: March 10, 1994Date of Patent: July 22, 1997Assignee: The Regents of the University of CaliforniaInventors: Fred H. Gage, Theodore Friedmann, Michael B. Rosenberg, Jon A. Wolff, Malcolm Schinstine, Michael D. Kawaja, Jasodhara Ray
-
Patent number: 5512421Abstract: The present application discloses retrovirus-derived vectors in which the retroviral envelope glycoprotein has been replaced by the G glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10.sup.9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.Type: GrantFiled: August 10, 1993Date of Patent: April 30, 1996Assignee: The Regents of the University of CaliforniaInventors: Jane C. Burns, Jiing-Kuan Yee, Theodore Friedmann
-
Patent number: 5082670Type: GrantFiled: December 15, 1988Date of Patent: January 21, 1992Assignee: The Regents of the University of CaliforniaInventors: Fred H. Gage, Michael B. Rosenberg, Theodore Friedmann